Larimar Therapeutics

Spero Therapeutics announced leadership changes with Esther Rajavelu as Interim President and CEO, and Frank Thomas as Chairman, following a Wells Notice from the SEC. The Phase 3 PIVOT-PO trial for Tebipenem HBr surpassed 60% enrollment, aiming for full enrollment by 2H 2025. The company's cash runway extends to mid-2026.

Friedreich’s Ataxia News highlighted 2024's top FA research and treatments, including vatiquinone's FDA approval pursuit, gene therapy advancements, and novel treatments like DT-216P2 and PPL-001. Studies showed improvements in FA symptoms, mitochondrial function, and heart defects in mice, aiming for better FA management.

The author discloses no stock positions in mentioned companies, no plans to initiate such positions within 72 hours, and no compensation for the article beyond Seeking Alpha. The article reflects personal opinions, with no business relationships to mentioned companies. Seeking Alpha emphasizes past performance doesn't guarantee future results and provides no investment advice.

Larimar Therapeutics reported positive initial data from its OLE study on nomlabofusp for Friedreich’s ataxia, showing increased FXN levels and early clinical improvement trends. The study is expanding to a 50 mg dose, with long-term data expected by mid-2025. Plans include a global confirmatory study and FDA discussions for accelerated approval.

Larimar Therapeutics reported initial data from an OLE study on nomlabofusp for FA, showing it's well-tolerated with mild adverse events. FXN levels increased in buccal and skin cells, indicating potential clinical benefits. The study also noted early improvement trends in clinical outcomes. Plans include dose increases and global site evaluations for further studies.

Larimar Therapeutics announced positive initial data from a long-term study of nomlabofusp for Friedreich's Ataxia, showing increased frataxin levels, potentially slowing disease progression. A registrational study is planned for mid-2025, with a Biologics License Application submission in late 2025.

Nomlabofusp treatment modifies gene expression, lipid profiles, and increases frataxin levels in Friedreich’s ataxia patients. Modeling predicts 50 mg daily achieves FXN levels ≥50% of healthy controls. Study participants represent the broad FA population, with consistent relationships between FXN levels and disease characteristics. Nomlabofusp program update expected mid-December 2024.

Nomlabofusp treatment in FA patients modified gene expression, lipid profiles, and increased FXN levels. Modeling predicts 50 mg daily achieves FXN levels ≥50% of healthy controls. Study participants' disease characteristics were representative of the broader FA population. Nomlabofusp program update expected mid-December 2024.

Trump's reelection may boost biotech innovation and M&A activity, potentially repealing the Inflation Reduction Act. Key roles in federal health agencies will influence drug pricing reforms. The Zacks Medical-Drugs industry, despite headwinds, shows promising trends with innovation in diabetes/obesity, inflammation, and neuroscience. Small drugmakers rely on collaboration partners and R&D funding, with notable stocks including Corcept Therapeutics, Madrigal Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, and Larimar Therapeutics.